Gary Robert Morrow, Ph.D., M.S.

Clinical Specialty

Research Overview

• American Cancer Society, predicting side effects of cancer treatment

  2005, $1,716,026.

• National Cancer Institute, assessing information needs of cancer patients undergoing chemotherapy and radiation therapy

  2002, $350,000.

• Alza Pharmaceutical; A phase II placebo-controlled trial of once daily methylphenidate in cancer patients with symptoms of fatigue related to radiation therapy

  2000-2002, $210,000.

• National Cancer Institute Grant throught NSABP, "NSABP Protocol P-2: A study of tamoxifen and raloxifene for the prevention of breast cancer," Principal Investigator for University of Rochester Cancer Center (URCC) Cancer Prevention Nework

  1999-2006, $620,000.

• American Cancer Society, "Institutional Reasearch Grant Award," Principal Investigator

  1999-2002, $240,000.

• United States Army Grant, "Preventing Fatigue in Women with Breast Cancer Treated with Chemotherapy," Principal Investigator

  1996-2001, $805,803.

• Nathan Cummings Foundation Grant, "Group Therapy for Women with Newly Diagnosed Breast Cancer and its Impact on Health," Principal Investigator

  1992-1999, $175,200

  Supplement: 1993-1999, $90,000.

• National Cancer Institute Grant, "University of Rochester Cancer Center Research Base for Community Clinical Oncology Program (CCOP)," Principal Investigator, 2U10-CA37420, 1991-2001

  2001, $645,000

• National Cancer Institute Grant, "Counseling Intervention for Chemotherapy Side Effects," Principal Investigator, R18-CA26832

  (most recent renewal)1994-1999, $1,297,644.

Selected Honors

• American Cancer Society Scientific Advisory Committee on Institutional Research Grants, 1991;
• Vice Chairman, 1993; Chairman, 1994
• Evan and Marion Helfaer Distinguished Lectureship, Medical College of Wisconsin, 1989
• New York State Governors Commission on Cancer Control, 1989-present
• Irene Lefton Leukemia Foundation Lectureship, November, 1988
• Board of Scientific Counselors, Illinois Cancer Council, 1987
• Research Career Development Award, 1985-90
• American Cancer Society Council on Research and Investigative Awards, 1984-1989
• Who's Who in the Biobehavioral Science, 1983
• Who's Who in Frontier Science and Technology, 1983
• Fellow, American Psychological Association, Division 38 (Health Psychology), 1983
• Academy of Behavioral Medicine Research, 1982
• American Cancer Society Scientific Advisory Committee on Clinical Investigations: Psychosocial and Behavioral Research, 1980-1984; Chairman, 1983-84
• American Cancer Society Scientific Advisory Committee on Prevention, Diagnosis and Therapy, 1978-80
• NDEA Fellowship, 1974-75
• Dean's Award (outstanding technical article of the year), Notre Dame, 1967
• Pi Tau Sigma (National Mechanical Engineering Honorary), Notre Dame, Chapter President, 1966-67
• Tau Kappa Alpha (National Forensic Honorary), Notre Dame, Chapter President, 1966-67
• Sophomore Engineer of the Year, Notre Dame, 1965
• Naval ROTC Scholarship, 1963-67
• Distinguished Paper Award, MAPSS, Temple University, 1961

Publications

1. Morrow, G.R., Hickok, J.T., Roscoe, J.A., Raubertas, R.F., Andrews, P.L.R. et al. The differential effects of Paroxetine on fatigue and depression: A URCC CCOP randomized, double-blind clinical trial of 479 patients receiving chemotherapy from community oncologists. J Clinical Oncology. (In press)
2. Shields, C.G., Morrow, G.R., Griggs, J.J., Mallinger, J., Roscoe, J.A., Wade, J.L., Dakhil, S.R., Fitch, T.R. Decision role preferences of patients receiving adjuvant cancer treatment: A university of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP). Supportive Cancer Therapy. Supportive Cancer Therapy. 2004, 83:87-89.
3. Pandya, K.J., Thummala, A.R., Griggs, J.J., Rosenblatt, J.D., Sahasrabudhe, D.M., Guttuso, T.J., Morrow, G.R., Roscoe, J.A. Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Research and Treatment. 2004, 83(1):87-89.
4. Hickok, J.T., Roscoe, J.A., Morrow, G.R., King, D.K., Atkins, J.N., Fitch, T.R. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5HT3 antiemetics: A URCC CCOP Study of 360 cancer patients treated in the community. Cancer. 2003, 97:2880-86
5. Roscoe, J.A., Morrow, G.R., Hickok, J.T., Bushunow, P. et al. The efficacy of acupressure and acustimultion wrist bands for the relief of chemotherapy-induced nausea and vomiting: A URCC CCOP multicenter study. Journal of Pain and Symptom Management. 2003, 26:731-42.
6. Kim, Y., Morrow, G.R., Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Supportive Care in Cancer. 2003, 11(3):171-77.
7. Morrow, G.R., Hickok, J.T., Andrews, P.L.R., and Stern, R. Reduction in serum cortisol following platinum- based chemotherapy. Psychophysiology. 2002, 39:491-95.
8. Kim,Y., Roscoe, J.A., Morrow, G.R. The effects of information and negative affect on severity of side effects from radiation therapy for prostate cancer. Supportive Care in Cancer. 2002, 10:416-21.
9. Matteson, S., Roscoe, J.A., Hickok J.T., Morrow, G.R. The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol. 2002, 186:S239-S243.
10. Morrow, G.R., Andrews, P.L.R., Hickok, J.T., Roscoe, J.A., Matteson, S. Fatigue associated with cancer and its treatment. Supportive Care in Cancer. 2002, 10:389-98.
11. Roscoe, J.A., Morrow, G.R., Bushunow, P., Tian, L., Matteson, S. Acustimulation wristbands for the relief of chemotherapy-induced nausea. Alternative Therapies in Health & Medicine. 2002, 8:56-63.
12. Roscoe, J.A., Morrow, G.R., Hickok, J.T., Bushunow, P., Matteson, S., Rakita, D., Andrews, P.L.R. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Supportive Care in Cancer. 2002, 10:329-36.
13. Morrow, G.R., Roscoe J.A., Hickok, J.T., Andrews, P.L.R., Matteson, S. Nausea and emesis: Evidence for a biobehavioral perspective. Supportive Care in Cancer. 2002, 10:96-105.
14. Koopman, C., Butler, L.D., Classen, C., GieseDavis, J., Morrow, G.R., Westendorf, J., Banerjee, T., Spiegel, D.
15. Traumatic stress symptoms among women with recently diagnosed primary breast cancer. Journal of Traumatic Stress. 2002, 15(4):277-87.
16. Gianaros, P.J., Stern, R.M., Morrow, G.R., Hickok, J.T. Relationship of gastric myoelectrical and cardiac parasympathetic activity to chemotherapy-induced nausea. Journal of Psychosomatic Research. 2001, 50:263-66.
17. Hickok, J.T., Roscoe, J.A., Morrow, G.R. The role of patients' expectations in the development of anticipatory nausea related to chemotherapy for cancer. Journal of Pain & Symptom Management. 2001, 22:843-50.
18. Pandya, K.J., Raubertas, R.F., Flynn, P.J., Morrow, G.R. et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med. 2000, 132:788-93.
19. Roscoe, J.A., Morrow, G.R., Hickok, J.T., Stern, R.M. Nausea and vomiting remain a significant clinical problem: Trends over time in controlling chemotherapy-induced nausea and vomiting in 1,413 patients treated in community clinical practices. Journal of Pain and Symptom Management. 2000, 20:113-121.
20. Morrow, G.R., Andrews, P.L.R., Hickok, J.T., Stern, R.M. Vagal changes following cancer chemotherapy; implications for the development of nausea. Psychophysiology. 2000, 37:378-84.
21. Roscoe, J.A., Hickok, J.T., Morrow, G.R. Patient expectations as predictor of chemotherapy-induced nausea. Annals of Behavioral Medicine. 2000, 22:121-126.
22. Nair, M.G., Hickok, J.T., Roscoe, J.A., Morrow, G.R. Sources of information used by patients to learn about chemotherapy side effects. J of Cancer Education. 2000, 15:19-22.
23. Hickok, J.T., Roscoe, J.A., Morrow, G.R., Stern, R.M., Yang, B., Flynn, P.J., Hynes, H.E., Kirshner, J.J., Rosenbluth, R.J. Use of 5-HT3 receptor antagonists to prevent nausea and vomiting caused by chemotherapy for breast cancer in community practice settings. Cancer. 1999, 86:64-71.
24. Spiegel, D., Morrow, G.R., Classen, C., Raubertas, R., Stott, P.B., Mudaliar, N. et al. Group psychotherapy for recently diagnosed breast cancer patients: A multicenter feasibility study. Psychooncology. 1999, 8: 482-93.
25. Morrow, G.R., Hickok, J.T., DuBeshter, B., Lipshultz, S. Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy induced nausea. Journal of the Autonomic Nervous System. 1999, 78:57-63.
26. Gralla R.J., Osoba, D., Kris, M.G., Kirkbrid, P., Hesketh, P.J., Chinnery, L.W., Morrow, G.R. et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999, 17:2971-94.
27. Morrow, G.R., Roscoe, J.A., Hickok, J.T., Stern, R.M., Pierce, H.I., King, D.B., Banerjee, T.K., Weiden, P.
28. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Hunting). 1998, 12:32-37.
29. Morrow, G.R., Roscoe, J.A., Kirshner, J.J., Hynes, H.E., Rosenbluth, R.J. Anticipatory nausea and vomiting:
30. In the era of 5-HT3 antiemetics. Supportive Care in Cancer. 1998, 6:244-247.
31. Morrow, G.R., Roscoe, J.A., Hynes, H.E., Flynn, P.J., Pierce, H.I., Burish, T. Progress in reducing anticipatory nausea and vomiting: A study of community practice. Supportive Care in Cancer. 1998, 6:46-50.
32. Morrow, G.R., Ballatori, E., Groshen, S., Olver, I. Statistical considerations in the design, conduct and analyses of antiemetic clinical trials. An emerging consensus. Supportive Care in Cancer. 1998, 6(3):261-265.
33. Classen, C., Abramson, S., Angell, K., Atkinson, A., Desch, C., Vinciguerra, V.P., Rosenbluth, R.J., Kirshner, J.J., Hart, R., Morrow, G.R., Spiegel, D. Effectiveness of a training program for enhancing therapists' understanding of the supportive-expressive treatment model for breast cancer groups. Journal of Psychotherapy Practice and Research. 1997, 6(3):211-218.
34. Muth, E.R., Morrow, G.R., Jiang, W., Stern, R.M., Dubeshter, B. Cardiac spectral power reflects parasympathetic but not sympathetic nervous system activity in a clinical population. Journal of the Autonomic Nervous System. 1996, 61(2):201-203.